Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
NCT00045422
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
OTHER
Sponsor class
Conditions
Leukemia
Interventions
BIOLOGICAL:
recombinant interferon alfa
DRUG:
imatinib mesylate
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
[object Object]